Gene One Life Science Inc

Capital Structure and Liquidity Gene One Life Science Inc exhibits a debt-to-equity ratio of 0.81, indicating a moderate reliance on debt financing [doc:valuation snapshot]. However, the company's liquidity position is weak, as evidenced by a current ratio of 0.36, which is significantly below the industry median [doc:valuation snapshot]. The company's cash and equivalents amount to KRW 1.3 billion, while its long-term debt stands at KRW 32.96 billion, resulting in a negative net cash position [doc:financial snapshot]. ### Profitability and Returns The company is currently unprofitable, with a net loss of KRW 51.85 billion and a return on equity (ROE) of -126.78% [doc:financial snapshot]. This performance is well below the industry median for ROE and return on assets (ROA), which are typically positive for firms in the biopharmaceutical and textile sectors [doc:valuation snapshot]. The negative gross profit of KRW 15.14 billion and operating loss of KRW 44.03 billion further underscore the company's operational challenges [doc:financial snapshot]. ### Segments and Geographic Exposure Gene One Life Science Inc operates in two primary segments: biopharmaceutical CDMO and textile manufacturing. The biopharmaceutical segment is likely the more capital-intensive and growth-oriented part of the business, while the textile segment contributes to revenue diversification. The company's geographic exposure is primarily concentrated in South Korea, with no significant international revenue disclosed in the latest financial data [doc:financial snapshot]. ### Growth Trajectory The company's revenue for the latest period is KRW 23.04 billion, but there is no indication of growth in the most recent period. The outlook for the current fiscal year (FY) and the next FY is not explicitly provided, but the negative operating and net income suggest a challenging growth environment. The company's capital expenditures are minimal at KRW 59.07 million, indicating a lack of significant investment in expansion or new projects [doc:financial snapshot]. ### Risk Factors The company faces medium liquidity risk due to its weak current ratio and negative net cash position [doc:risk assessment]. The risk of dilution is currently low, but the company's negative free cash flow of KRW 33.77 billion and operating cash flow of KRW 16.54 billion indicate a need for external financing, which could lead to future dilution [doc:financial snapshot]. The company's risk assessment also flags the negative net cash position as a key concern [doc:risk assessment]. ### Recent Events There are no specific recent events or filings mentioned in the provided data that would indicate significant changes in the company's operations or financial position. The company's recent performance is primarily reflected in its financial statements, which show continued losses and declining liquidity [doc:financial snapshot].